Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma in situ involving a anal canal.
Biomarker and diagnostic research for anal canal carcinoma in situ has been reported in the published literature.
1 clinical trial registered. Pipeline includes 1 PHASE2.
10 publications have been identified in PubMed for anal canal carcinoma in situ. Research spans Epidemiology / Natural History (40%), Diagnostic / Biomarker (20%), and Other (10%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 4 | 40% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:39 PM UTC
2 |
20% |
Other research | 1 | 10% |
Research summaries | 1 | 10% |
Patient case studies | 1 | 10% |
Laboratory research | 1 | 10% |
Shao X (2026). [PMID: 41989714](https://pubmed.ncbi.nlm.nih.gov/41989714/). *Clin J Gastroenterol*. [Case Report / Case Series]
Chen F (2026). [PMID: 41759921](https://pubmed.ncbi.nlm.nih.gov/41759921/). *Archives of pathology & laboratory medicine*. [Epidemiology / Natural History]
Feltes Ochoa RA (2025). [PMID: 39389343](https://pubmed.ncbi.nlm.nih.gov/39389343/). *Actas dermo-sifiliograficas*. [Epidemiology / Natural History]
Villoslada A (2025). [PMID: 40923874](https://pubmed.ncbi.nlm.nih.gov/40923874/). *Journal of medical virology*. [Epidemiology / Natural History]
Okumura T (2025). [PMID: 39760965](https://pubmed.ncbi.nlm.nih.gov/39760965/). *Clinical journal of gastroenterology*. [Diagnostic / Biomarker]
Pedersen TB (2025). [PMID: 40801169](https://pubmed.ncbi.nlm.nih.gov/40801169/). *The Cochrane database of systematic reviews*. [Review / Meta-Analysis]
Junejo MH (2025). [PMID: 39212481](https://pubmed.ncbi.nlm.nih.gov/39212481/). *Clinical and experimental dermatology*. [Other]
Dapper H (2025). [PMID: 40053135](https://pubmed.ncbi.nlm.nih.gov/40053135/). *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]*. [Epidemiology / Natural History]
Pineda Contreras S (2025). [PMID: 40086119](https://pubmed.ncbi.nlm.nih.gov/40086119/). *Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia*. [Basic Science / Preclinical]
Fernandez-Alonso V (2024). [PMID: 38557433](https://pubmed.ncbi.nlm.nih.gov/38557433/). *Human vaccines & immunotherapeutics*. [Diagnostic / Biomarker]
AI-curated news mentioning anal canal carcinoma in situ
Updated Aug 31, 2026
Recent research explores therapeutic approaches for metastatic or unresectable recurrent anal canal cancer, highlighting emerging perspectives in treatment strategies. This study contributes to the understanding of this rare cancer's management.
A retrospective cohort study highlights the prognostic significance of systemic inflammatory indices in patients with squamous cell carcinoma of the anal canal. This research may inform future clinical assessments and treatment strategies.